Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.
PDF (1.9M)
+4 authors
Journal: 1997/January - Gut
ISSN: 0017-5749
PUBMED: 8949646
Abstract:
BACKGROUND
Reactive oxygen species may mediate tissue injury in inflammatory bowel disease. Aminosalicylates have antioxidant activity and the antioxidants, superoxide dismutase and allopurinol, are of reported benefit in inflammatory bowel disease.
OBJECTIVE
To develop a convenient technique for testing the antioxidant potential of standard and novel therapeutic agents for use in inflammatory bowel disease.
METHODS
Amplified chemiluminescence was used to measure reactive oxygen species production by colonic biopsy specimens from rats with acetic acid induced colitis and to assess the in vitro effect of conventional antioxidants, standard therapies and proposed novel therapies for inflammatory bowel disease.
RESULTS
The model was validated by demonstrating that the profile of effects on chemiluminescence of acetic acid induced colitis biopsy specimens given by conventional antioxidants (sodium azide, catalase, copper-zinc superoxide dismutase, dimethyl sulphoxide, N-acetylcysteine and ascorbate) and standard therapies (5-aminosalicylate and hydrocortisone) resembled that previously reported using biopsy specimens from ulcerative colitis. Human recombinant manganese superoxide dismutase did not alter chemiluminescence. Two novel compounds, LY231617 (10 mM) and amflutizole (20 mM), reduced chemiluminescence by 98% (n = 5, p = 0.009) and 88% (n = 5, p = 0.03), respectively.
CONCLUSIONS
The similarity of the chemiluminescence responses of colonic biopsy specimens from acetic acid induced colitis and ulcerative colitis to a range of conventional antioxidants and standard treatments suggests that this model is a useful method for testing the antioxidant potential of new therapies for inflammatory bowel disease. The antioxidant actions of dimethyl sulphoxide, ascorbate, and the novel compounds, amflutizole and LY231617 in this model suggest that these agents merit further assessment in the treatment of inflammatory bowel disease.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(57)
References
(49)
Diseases
(3)
Drugs
(16)
Chemicals
(5)
Organisms
(3)
Anatomy
(1)
Similar articles
Articles by the same authors
Discussion board
Gut 39(3): 407-415
PMID: 8949646

Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.

Abstract

BACKGROUND: Reactive oxygen species may mediate tissue injury in inflammatory bowel disease. Aminosalicylates have antioxidant activity and the antioxidants, superoxide dismutase and allopurinol, are of reported benefit in inflammatory bowel disease. AIM: To develop a convenient technique for testing the antioxidant potential of standard and novel therapeutic agents for use in inflammatory bowel disease. METHODS: Amplified chemiluminescence was used to measure reactive oxygen species production by colonic biopsy specimens from rats with acetic acid induced colitis and to assess the in vitro effect of conventional antioxidants, standard therapies and proposed novel therapies for inflammatory bowel disease. RESULTS: The model was validated by demonstrating that the profile of effects on chemiluminescence of acetic acid induced colitis biopsy specimens given by conventional antioxidants (sodium azide, catalase, copper-zinc superoxide dismutase, dimethyl sulphoxide, N-acetylcysteine and ascorbate) and standard therapies (5-aminosalicylate and hydrocortisone) resembled that previously reported using biopsy specimens from ulcerative colitis. Human recombinant manganese superoxide dismutase did not alter chemiluminescence. Two novel compounds, LY231617 (10 mM) and amflutizole (20 mM), reduced chemiluminescence by 98% (n = 5, p = 0.009) and 88% (n = 5, p = 0.03), respectively. CONCLUSIONS: The similarity of the chemiluminescence responses of colonic biopsy specimens from acetic acid induced colitis and ulcerative colitis to a range of conventional antioxidants and standard treatments suggests that this model is a useful method for testing the antioxidant potential of new therapies for inflammatory bowel disease. The antioxidant actions of dimethyl sulphoxide, ascorbate, and the novel compounds, amflutizole and LY231617 in this model suggest that these agents merit further assessment in the treatment of inflammatory bowel disease.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 407
407
icon of scanned page 408
408
icon of scanned page 409
409
icon of scanned page 410
410
icon of scanned page 411
411
icon of scanned page 412
412
icon of scanned page 413
413
icon of scanned page 414
414
icon of scanned page 415
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology. 1992 Jul;103(1):186–196. [PubMed] [Google Scholar]
  • Sedghi S, Fields JZ, Klamut M, Urban G, Durkin M, Winship D, Fretland D, Olyaee M, Keshavarzian A. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut. 1993 Sep;34(9):1191–1197.[PMC free article] [PubMed] [Google Scholar]
  • Babbs CF. Oxygen radicals in ulcerative colitis. Free Radic Biol Med. 1992;13(2):169–181. [PubMed] [Google Scholar]
  • Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994 Sep 24;344(8926):859–861. [PubMed] [Google Scholar]
  • Repine JE, Eaton JW, Anders MW, Hoidal JR, Fox RB. Generation of hydroxyl radical by enzymes, chemicals, and human phagocytes in vitro. Detection with the anti-inflammatory agent, dimethyl sulfoxide. J Clin Invest. 1979 Dec;64(6):1642–1651.[PMC free article] [PubMed] [Google Scholar]
  • Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988 Mar;33(3 Suppl):6S–15S. [PubMed] [Google Scholar]
  • Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology. 1985 Nov;89(5):1162–1188. [PubMed] [Google Scholar]
  • Grisham MB, MacDermott RP, Deitch EA. Oxidant defense mechanisms in the human colon. Inflammation. 1990 Dec;14(6):669–680. [PubMed] [Google Scholar]
  • Riendeau D, Denis D, Choo LY, Nathaniel DJ. Stimulation of 5-lipoxygenase activity under conditions which promote lipid peroxidation. Biochem J. 1989 Oct 15;263(2):565–572.[PMC free article] [PubMed] [Google Scholar]
  • Zimmerman BJ, Grisham MB, Granger DN. Role of oxidants in ischemia/reperfusion-induced granulocyte infiltration. Am J Physiol. 1990 Feb;258(2 Pt 1):G185–G190. [PubMed] [Google Scholar]
  • Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991 Aug;10(8):2247–2258.[PMC free article] [PubMed] [Google Scholar]
  • Amstad PA, Krupitza G, Cerutti PA. Mechanism of c-fos induction by active oxygen. Cancer Res. 1992 Jul 15;52(14):3952–3960. [PubMed] [Google Scholar]
  • Ahnfelt-Rønne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 1990 May;98(5 Pt 1):1162–1169. [PubMed] [Google Scholar]
  • Emerit J, Pelletier S, Likforman J, Pasquier C, Thuillier A. Phase II trial of copper zinc superoxide dismutase (CuZn SOD) in the treatment of Crohn's disease. Free Radic Res Commun. 1991;12-13 Pt 2:563–569. [PubMed] [Google Scholar]
  • Levin KE, Pemberton JH, Phillips SF, Zinsmeister AR, Pezim ME. Role of oxygen free radicals in the etiology of pouchitis. Dis Colon Rectum. 1992 May;35(5):452–456. [PubMed] [Google Scholar]
  • Keshavarzian A, Sedghi S, Kanofsky J, List T, Robinson C, Ibrahim C, Winship D. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology. 1992 Jul;103(1):177–185. [PubMed] [Google Scholar]
  • Yoshikawa T, Takahashi S, Kondo M. Possible role of free radicals in the chronic inflammation of the gut. EXS. 1992;62:353–358. [PubMed] [Google Scholar]
  • Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease. Gastroenterology. 1985 Jan;88(1 Pt 1):55–63. [PubMed] [Google Scholar]
  • Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut. 1990 Jul;31(7):786–790.[PMC free article] [PubMed] [Google Scholar]
  • Keshavarzian A, Haydek J, Zabihi R, Doria M, D'Astice M, Sorenson JR. Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis. Dig Dis Sci. 1992 Dec;37(12):1866–1873. [PubMed] [Google Scholar]
  • Inflammatory bowel disease. Gut. 1992;33(1 Suppl):S7–S8.[PMC free article][Google Scholar]
  • MacPherson BR, Pfeiffer CJ. Experimental production of diffuse colitis in rats. Digestion. 1978;17(2):135–150. [PubMed] [Google Scholar]
  • Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989 Mar;96(3):795–803. [PubMed] [Google Scholar]
  • Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276.[PMC free article] [PubMed] [Google Scholar]
  • Maridonneau-Parini I, Errasfa M, Russo-Marie F. Inhibition of O2- generation by dexamethasone is mimicked by lipocortin I in alveolar macrophages. J Clin Invest. 1989 Jun;83(6):1936–1940.[PMC free article] [PubMed] [Google Scholar]
  • Nurcombe HL, Edwards SW. Role of myeloperoxidase in intracellular and extracellular chemiluminescence of neutrophils. Ann Rheum Dis. 1989 Jan;48(1):56–62.[PMC free article] [PubMed] [Google Scholar]
  • Hallett MB, Campbell AK. Two distinct mechanisms for stimulation of oxygen-radical production by polymorphonuclear leucocytes. Biochem J. 1983 Nov 15;216(2):459–465.[PMC free article] [PubMed] [Google Scholar]
  • McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985 Jan 17;312(3):159–163. [PubMed] [Google Scholar]
  • Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet. 1989 Nov 4;2(8671):1057–1062. [PubMed] [Google Scholar]
  • Oshitani N, Kitano A, Okabe H, Nakamura S, Matsumoto T, Kobayashi K. Location of superoxide anion generation in human colonic mucosa obtained by biopsy. Gut. 1993 Jul;34(7):936–938.[PMC free article] [PubMed] [Google Scholar]
  • Mulder TP, Verspaget HW, Janssens AR, de Bruin PA, Peña AS, Lamers CB. Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease. Gut. 1991 Oct;32(10):1146–1150.[PMC free article] [PubMed] [Google Scholar]
  • Niwa Y, Somiya K, Michelson AM, Puget K. Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free Radic Res Commun. 1985;1(2):137–153. [PubMed] [Google Scholar]
  • Gorecki M, Beck Y, Hartman JR, Fischer M, Weiss L, Tochner Z, Slavin S, Nimrod A. Recombinant human superoxide dismutases: production and potential therapeutical uses. Free Radic Res Commun. 1991;12-13 Pt 1:401–410. [PubMed] [Google Scholar]
  • Parizada B, Werber MM, Nimrod A. Protective effects of human recombinant MnSOD in adjuvant arthritis and bleomycin-induced lung fibrosis. Free Radic Res Commun. 1991;15(5):297–301. [PubMed] [Google Scholar]
  • Suzuki M, Grisham MB, Granger DN. Leukocyte-endothelial cell adhesive interactions: role of xanthine oxidase-derived oxidants. J Leukoc Biol. 1991 Nov;50(5):488–494. [PubMed] [Google Scholar]
  • Bilotta JJ, Waye JD. Hydrogen peroxide enteritis: the "snow white" sign. Gastrointest Endosc. 1989 Sep-Oct;35(5):428–430. [PubMed] [Google Scholar]
  • Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593–597. [PubMed] [Google Scholar]
  • Nishikimi M. Oxidation of ascorbic acid with superoxide anion generated by the xanthine-xanthine oxidase system. Biochem Biophys Res Commun. 1975 Mar 17;63(2):463–468. [PubMed] [Google Scholar]
  • Halliwell B, Wasil M, Grootveld M. Biologically significant scavenging of the myeloperoxidase-derived oxidant hypochlorous acid by ascorbic acid. Implications for antioxidant protection in the inflamed rheumatoid joint. FEBS Lett. 1987 Mar 9;213(1):15–17. [PubMed] [Google Scholar]
  • Pettit SH, Shaffer JL, Johns CW, Bennett RJ, Irving MH. Ascorbic acid absorption in Crohn's disease. Studies using L-[carboxyl-14C]ascorbic acid. Dig Dis Sci. 1989 Apr;34(4):559–566. [PubMed] [Google Scholar]
  • Rowley DA, Halliwell B. Formation of hydroxyl radicals from hydrogen peroxide and iron salts by superoxide- and ascorbate-dependent mechanisms: relevance to the pathology of rheumatoid disease. Clin Sci (Lond) 1983 Jun;64(6):649–653. [PubMed] [Google Scholar]
  • Phillis JW, Sen S, Cao X. Amflutizole, a xanthine oxidase inhibitor, inhibits free radical generation in the ischemic/reperfused rat cerebral cortex. Neurosci Lett. 1994 Mar 14;169(1-2):188–190. [PubMed] [Google Scholar]
  • Sharonov BP, Govorova NJu, Lyzlova SN. Serum protein degradation by hypochlorite. Biochem Int. 1989 Jul;19(1):27–35. [PubMed] [Google Scholar]
  • Dallegri F, Ottonello L, Ballestrero A, Bogliolo F, Ferrando F, Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut. 1990 Feb;31(2):184–186.[PMC free article] [PubMed] [Google Scholar]
  • Green TR, Fellman JH, Eicher AL, Pratt KL. Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils. Biochim Biophys Acta. 1991 Jan 23;1073(1):91–97. [PubMed] [Google Scholar]
  • Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med. 1987 Jul;110(1):91–96. [PubMed] [Google Scholar]
  • Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987 Feb;28(2):190–195.[PMC free article] [PubMed] [Google Scholar]
  • Craven PA, Pfanstiel J, Saito R, DeRubertis FR. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology. 1987 Jun;92(6):1998–2008. [PubMed] [Google Scholar]
  • Aruoma OI, Wasil M, Halliwell B, Hoey BM, Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem Pharmacol. 1987 Nov 1;36(21):3739–3742. [PubMed] [Google Scholar]
  • Grisham MB. Effect of 5-aminosalicylic acid on ferrous sulfate-mediated damage to deoxyribose. Biochem Pharmacol. 1990 Jun 15;39(12):2060–2063. [PubMed] [Google Scholar]
Gastrointestinal Science Unit, London Hospital Medical College.
Gastrointestinal Science Unit, London Hospital Medical College.
Copyright notice
Abstract
BACKGROUND: Reactive oxygen species may mediate tissue injury in inflammatory bowel disease. Aminosalicylates have antioxidant activity and the antioxidants, superoxide dismutase and allopurinol, are of reported benefit in inflammatory bowel disease. AIM: To develop a convenient technique for testing the antioxidant potential of standard and novel therapeutic agents for use in inflammatory bowel disease. METHODS: Amplified chemiluminescence was used to measure reactive oxygen species production by colonic biopsy specimens from rats with acetic acid induced colitis and to assess the in vitro effect of conventional antioxidants, standard therapies and proposed novel therapies for inflammatory bowel disease. RESULTS: The model was validated by demonstrating that the profile of effects on chemiluminescence of acetic acid induced colitis biopsy specimens given by conventional antioxidants (sodium azide, catalase, copper-zinc superoxide dismutase, dimethyl sulphoxide, N-acetylcysteine and ascorbate) and standard therapies (5-aminosalicylate and hydrocortisone) resembled that previously reported using biopsy specimens from ulcerative colitis. Human recombinant manganese superoxide dismutase did not alter chemiluminescence. Two novel compounds, LY231617 (10 mM) and amflutizole (20 mM), reduced chemiluminescence by 98% (n = 5, p = 0.009) and 88% (n = 5, p = 0.03), respectively. CONCLUSIONS: The similarity of the chemiluminescence responses of colonic biopsy specimens from acetic acid induced colitis and ulcerative colitis to a range of conventional antioxidants and standard treatments suggests that this model is a useful method for testing the antioxidant potential of new therapies for inflammatory bowel disease. The antioxidant actions of dimethyl sulphoxide, ascorbate, and the novel compounds, amflutizole and LY231617 in this model suggest that these agents merit further assessment in the treatment of inflammatory bowel disease.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.